Zepbound's suicidal ideation warning removed and its severe gastrointestinal section updated

The prescribing information for Zepbound (tirzepatide) no longer includes a warning about suicidal behavior and ideation. The label's "Recent Major Changes" table records the entry "Suicidal Behavior and Ideation (Removed)" with a date of 02/2026, alongside an update to "Severe Gastrointestinal Adverse Reactions (5.2)" in the same month ^[1][2].

Those two February 2026 entries appear in the version of the label revised 08/2026 and posted to the FDA's label archive as application 217806, supplement 41 ^[2]. DailyMed lists the same document as updated August 28, 2026 ^[1]. The Recent Major Changes table also shows Dosage and Administration (2.4) changed in 01/2026, "Never Share a ZEPBOUND KwikPen Between Patients" (5.10) in 01/2026, and Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus (5.8) in 08/2026 ^[1][2].

What the label says now

The current Warnings and Precautions section runs from 5.1 through 5.10 and contains no subsection on suicidal behavior or ideation ^[1][2]. The listed warnings are: risk of thyroid C-cell tumors, severe gastrointestinal adverse reactions, acute kidney injury due to volume depletion, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, hypoglycemia, diabetic retinopathy complications in people with type 2 diabetes, pulmonary aspiration during general anesthesia or deep sedation, and the instruction never to share a KwikPen between patients ^[1][2].

Section 5.2 still states that use of Zepbound "has been associated with gastrointestinal adverse reactions, sometimes severe," and that the drug "is not recommended in patients with severe gastroparesis" ^[1][2]. The dosing section ties the four-week escalation steps, starting at 2.5 mg once weekly and rising in 2.5 mg increments to a maximum of 15 mg once weekly, to reducing the risk of gastrointestinal adverse reactions ^[2]. The label lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation (burping), hair loss and gastroesophageal reflux disease as adverse reactions reported in at least 5% of patients treated with Zepbound ^[1][2].

The boxed warning about thyroid C-cell tumors seen in rats is unchanged, as is the contraindication for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 ^[1][2].

What the documents do not include is any explanation. The label records that the suicidality warning was removed and that section 5.2 was revised, but neither the FDA label PDF nor the DailyMed listing provided here states the reasoning, the underlying data, or exactly which sentences in 5.2 changed ^[1][2]. Comparable revision histories for other GLP-1 products are not contained in these sources, so this article cannot confirm from the record here how other labels were handled.

Why it matters for patients

Label warnings shape what prescribers discuss at appointments, what pharmacists flag, and what appears in the Medication Guide that comes with a prescription ^[1][2]. Removing a warning section means clinicians reading the current Zepbound prescribing information will no longer see suicidal behavior and ideation listed among the drug's warnings and precautions ^[1][2].

A removal from the label is an administrative record of a change in the approved text. It does not, by itself, tell a patient anything about their own mental health history or how a clinician should monitor them. People who started tirzepatide earlier may have received older printed materials or a Medication Guide that still referenced the warning; the current official version on DailyMed reflects the 08/2026 revision ^[1].

The gastrointestinal warning, by contrast, remains in place and was updated rather than dropped. GI side effects are the most commonly reported problems with this drug, and the label continues to say Zepbound is not recommended for people with severe gastroparesis ^[1][2].

What happens next

The dated milestones in the record are: 01/2026 changes to dosing instructions and KwikPen sharing language; 02/2026 removal of the suicidality warning and update to section 5.2; and 08/2026 changes to the diabetic retinopathy section, with the full label revised 08/2026 and posted to DailyMed on August 28, 2026 ^[1][2]. Whether further revisions follow is not stated in these documents. Suspected adverse reactions can be reported to Eli Lilly at 1-800-545-5979 or to the FDA at 1-800-FDA-1088 ^[1][2].